glycerol phenylbutyrate glycerol phenylbutyrate glycerol phenylbutyrate (usan), trade name ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. the medication works by preventing the harmful buildup of ammonia in the body. it is an fda-approved prescription drug in the us. it is approved for anyone over 2 months of age. it was developed by hyperion therapeutics based on the existing drug buphenyl, and received approval on february 1, 2013. hyperion has been criticized for setting a high price for the drug. the price was set at us$250,000–290,000. in 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive buphenyl ($113.6 million in sales). in march 2015, horizon pharma acquired hyperion therapeutics and thus raviciti. glycerol phenylbutyrateclinical datatrade namesravictiahfs/drugs.commicromedex detailed consumer informationlicense data eu ema: by inn routes ofadministrationby mouthatc codea16ax09 (who) legal statuslegal status us: ℞-only eu: rx-only identifiers iupac name 1,2,3-propanetriyl tris(4-phenylbutanoate) cas number611168-24-2 ypubchem cid10482134drugbankdb08909chemspider8657541uniizh6f1vcv7bchemblchembl2105745comptox dashboard (epa)dtxsid40210005 echa infocard100.228.552 chemical and physical dataformulac33h38o6molar mass530.661 g·mol−13d model (jsmol)interactive image smiles c1=cc=c(c=c1)cccc(=o)occ(coc(=o)cccc2=cc=cc=c2)oc(=o)cccc3=cc=cc=c3 inchi inchi=1s/c33h38o6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30h,10-12,19-26h2key:zsdbflmjvagkou-uhfffaoysa-n